China’s Asieris Bets On Bladder Cancer With Rediscovered Asset From Johns Hopkins

Emerging Company Profile: Aiming to change the current practice of surgically removing the bladder, China Asieris hopes to use an older drug to treat early-onset bladder cancer. This is the fourth and last in a series of China-based Emerging Company Profiles.

Emerging Company Profile Regular column feature image Version 2

There are roughly 80,000 newly diagnosed bladder cancer cases each year in China and 70-80% are early-stage cancers, otherwise known as non-muscle invasive bladder cancer (NMIBC). The current standard care for high-risk patients who failed intravesical therapies is surgical removal of the bladder, which drastically lowers the patient’s quality of life.

Now, Shanghai-based Asieris Pharma is developing an old antibiotic – a methionine aminopeptidase II (MetAP2) inhibitor – as

China Unbound: Fourth In A Series

China has seen explosive growth in developing new drugs ranging from antibodies to cell therapies, hence the first report from a new series covering emerging biotechs in China. They range from anti-cancer developers to respiratory specialty firms, from Shanghai to Zhongshan – several made-in-China biopharma innovators that largely have been flying under the radar.

See the first three articles in this series here: Hepalink-Backed HighTide Bets On NASH For Global Markets,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia